Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone. Therefore, the combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result in similar toxicities [see Warnings and Precautions ].
Live vaccines should not be given concurrently with HUMIRA [see Warnings and Precautions].
Humira has been studied in rheumatoid arthritis patients taking concomitant methotrexate. Although methotrexate reduced the apparent adalimumab clearance [see Clinical Pharmacology], the data do not suggest the need for dose adjustment of either HUMIRA or methotrexate.